Glycoproteins Antagonists Inhibitors
Mostrando 1-3 de 3 artigos, teses e dissertações.
-
1. "Análise volumétrica da hiperplasia intimal intra-stent em pacientes diabéticos tratados com e sem abciximab" / Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab
Ninety-six type 2 diabetics were randomly assigned to receive abciximab or no abciximab at the time of elective stent implantation to determine whether this IIb/IIIa glycoprotein inhibitor would reduce in-stent intimal hyperplasia, measured by intravascular ultrasound, at 6-month follow-up. Volumetric analysis showed that abciximab was not associated with a
Publicado em: 2004
-
2. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages.
Alveolar macrophages have been shown to bind glycoproteins and synthetic glycoconjugates (neoglycorpoteins) that have mannose, N-acetylglucosamine, or glucose in the exposed, nonreducing position. Galactose-terminal glycoproteins are not bound. Binding of radiolabeled ligands to cells is nearly completely impaired by the presence of an excess of yeast mannan
-
3. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
HIV-1 entry into CD4+ cells requires the sequential interactions of the viral envelope glycoproteins with CD4 and a coreceptor such as the chemokine receptors CCR5 and CXCR4. A plausible approach to blocking this process is to use small molecule antagonists of coreceptor function. One such inhibitor has been described for CCR5: the TAK-779 molecule. To facil
The National Academy of Sciences.